Medical research has shaped the treatments and healthcare practices used today. However, historically, it has failed to account for sex-based differences in disease presentation, treatment responses, and overall health outcomes. For decades, women have been underrepresented in clinical trials, which has resulted in gaps in medical knowledge that affect everything from drug efficacy to disease management.

Don’t believe it? Recent studies highlight the extent of the issue, as a 2023 report from the British Medical Journal revealed that only 41% of participants in UK-based clinical trials were female. Sadly, many trials still exclude women due to concerns over hormonal fluctuations, leaving medical professionals without accurate data on how treatments impact half the population. Without action, misdiagnoses, ineffective treatments, and higher rates of adverse drug reactions will continue to affect women’s health.

The rise of FemTech—technology designed to address women’s health needs—offers a potential solution. Thanks to leveraging digital tools, AI-driven data collection, and real-world evidence, FemTech is reshaping clinical research and paving the way for gender-inclusive healthcare advancements, and here’s how.

The Gender Gap in Clinical Research: Where Are We Now?

Women continue to be underrepresented in clinical research, with disparities persisting across multiple medical fields. Cardiovascular disease, for example, is the leading cause of death among women in the UK. Despite this, a 2023 report from the British Cardiovascular Society highlighted that women are significantly less likely to be included in trials for new treatments. Research into conditions that predominantly affect women, such as endometriosis and polycystic ovary syndrome (PCOS), also remains underfunded, leading to prolonged diagnostic delays and limited treatment options.

Recent regulatory efforts aim to improve representation. The European Medicines Agency has updated its guidelines to require more sex-specific data analysis in clinical trials. However, implementation remains inconsistent, with many research institutions yet to adopt clear policies ensuring equal representation. Without systemic changes, women will continue to receive medical treatments developed using incomplete or male-biased data, increasing the risk of misdiagnoses and inadequate care.

Leveraging Education and Awareness to Drive Change

Of course, public awareness plays a critical role in addressing research disparities. Many healthcare professionals lack training in gender-specific medicine, contributing to diagnostic delays and ineffective treatments. Universities can bridge this gap by integrating women’s health topics into university courses, ensuring future medical professionals are equipped to challenge outdated practices.

What about those looking to specialise in this field? Fortunately, there are plenty of opportunities, making it possible to find a degree course at a UK university that focuses on gender-inclusive research and digital health advancements. Widespread education efforts, including public health campaigns and professional training, will drive long-term improvements in research inclusivity.

Addressing Bias in Medical Trials Through Technology

Sadly, bias remains a persistent issue in clinical trials. Women are often excluded from research due to concerns over hormonal variability, yet this exclusion leads to incomplete medical knowledge. A study published in the American Journal of Medicine found that women are underrepresented as participants, authors, lead authors, and leadership committees in cardiovascular randomised controlled trials (RCTs), limiting the ability to perform sex-disaggregated analysis and generalise findings to women.

AI and machine learning tools can help correct these disparities. Algorithm-driven trial design ensures balanced participation by identifying gaps in enrolment and recruiting diverse populations. Integrating FemTech data further strengthens this approach by capturing real-world insights into conditions that disproportionately affect women, such as endometriosis and autoimmune disorders.

The Role of Digital Health in Personalised Research

Personalised medicine is transforming healthcare, with digital health tools accelerating this paradigm shift. Standard treatments often fail to account for individual differences in genetics, hormones, and lifestyle factors. With AI-driven diagnostics and wearable technology becoming increasingly sophisticated, medical professionals can develop treatments tailored to an individual’s unique biology.

Recent advances demonstrate the potential impact of this approach. Research published in the Journal of Clinical Endocrinology & Metabolism shows that AI and machine learning approaches can significantly improve the prediction of menopause timing compared to traditional methods. These insights enable more proactive management of symptoms and better long-term health outcomes—a significant advancement in women’s healthcare.

Regulatory Challenges and Opportunities for FemTech Solutions

Integrating FemTech into mainstream healthcare requires navigating complex regulatory frameworks. Historically, digital health solutions faced challenges due to stringent approval processes. However, the MHRA has introduced initiatives to address these issues.​

In January 2024, the MHRA published its roadmap for delivering a future regulatory framework for medical devices. This roadmap aims to provide consistency, clarity, and continuous improvement, fostering a more supportive environment for medical technology innovations, including FemTech. ​

Additionally, the Innovative Devices Access Pathway (IDAP) pilot was launched to reduce uncertainty in the route to market for technology developers. This initiative stems from the Life Sciences Vision, aiming to enable and improve patient access to innovative and transformative medical devices by providing integrated regulatory and access support to developers. These efforts indicate a shift towards a more accommodating regulatory environment for FemTech solutions, enhancing their potential to be integrated into mainstream healthcare.​

Policymakers are also focusing on creating a thriving life sciences sector. The UK’s Life Sciences Vision outlines plans to stimulate the sector, address significant healthcare challenges, and emphasise the integration of innovative technologies. ​Advocating for FemTech’s inclusion in clinical research guidelines and leveraging these supportive regulatory frameworks will ensure these innovations reach the patients who need them most.​

How Data-Driven Innovation Could Improve Outcomes for Women

Leveraging big data is essential to closing the gender gap in healthcare. By aggregating information from FemTech applications, researchers can develop more precise treatment strategies tailored to female biology. This approach has the potential to reduce misdiagnosis rates and ensure medical advancements serve women more effectively.​

Collaboration between FemTech companies, academic institutions, and healthcare providers is already driving change. For instance, AI-powered virtual assistants are being developed to provide personalised support and information related to menopausal symptoms. In 2024, Mira Care launched its AI-powered ‘Menopause Transitions Kit’ for at-home hormone monitoring, allowing users to track key reproductive hormones and personalise menopause management accordingly. ​

These advancements highlight how data-driven innovation is leading to more personalised, effective treatments for women. Increased investment in FemTech collaborations could further refine diagnostic tools and ensure that medical research reflects the full spectrum of female health experiences.

Embracing these technological advancements and fostering collaborations means the healthcare industry can make significant strides toward closing the gender gap in clinical research and treatment outcomes.​

Encouraging Greater Female Participation in Clinical Studies

Many women remain unaware of opportunities to participate in clinical trials. FemTech platforms can help by providing personalised trial recommendations based on a user’s health profile. Ensuring flexible study designs, offering compensation, and addressing safety concerns can further encourage participation. More inclusive trials mean better data, leading to improved medical treatments for women.

Driving Lasting Change in Medical Research

FemTech is reshaping how women’s health is studied, offering a powerful tool to close research gaps and improve healthcare outcomes. With continued investment, regulatory support, and public engagement, these innovations will drive lasting change in clinical research, though institutional adaptation may require sustained effort.

The transition towards inclusive, data-driven healthcare requires coordinated action across multiple sectors. Researchers, policymakers, and technology leaders must collaborate to ensure medical studies reflect the needs of all patients, not those who align with traditional research parameters. Strengthening these efforts will not only advance women’s healthcare but also enhance the quality and applicability of medical research overall—creating a more equitable and effective healthcare system for everyone.